Pharma has functioned as a defensive income anchor for decades, and the logic was always straightforward: patent-protected drugs carry wide margins, demand is inelastic, and the dividends keep climbing regardless of what equities do in any given quarter. That logic is about to face a real stress test.
The new Section 232 duties took effect at 12:01 a.m. Eastern time on July 31, 2026, for the companies listed in Annex III, and they take effect at 12:01 a.m. Eastern time on September 29, 2026, for all other companies. That second date is sixteen days away. The proclamation imposes a 100% ad valorem duty rate on imports of patented pharmaceutical articles and associated pharmaceutical ingredients, with a temporary 0% additional duty rate for non-Annex III companies only until the September 29 effective time. Generic pharmaceuticals and their associated ingredients are not subject to these Section 232 tariffs at this time, and the proclamation also sets out carve-outs for specified specialty categories (including orphan-drug-only indications) under stated conditions.
Annex III is a who’s-who of large pharma: AbbVie, Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme, Novartis, and Pfizer, among others. Those names have been operating under the tariff since July 31. The September 29 deadline extends the same regime to the rest of the industry.
This is the week management teams have to answer for it publicly. The Morgan Stanley 24th Annual Global Healthcare Conference runs September 14 through 16 in New York. Eli Lilly will participate on September 14. Johnson & Johnson presents the same morning at 11:30 a.m. Eastern. Amgen follows on September 15 at 11:30 a.m. Eastern. Every fireside chat this week is an opportunity for CFOs to quantify what the tariff actually costs, or to stay vague about it, which is itself informative.
The dividend math matters here. J&J declared its 64th consecutive annual dividend increase in 2026, raising the quarterly payout 3.1% to $1.34. That Dividend King status rests on a highly rated balance sheet, roughly 21.8% profit margins, and about $19.7 billion in free cash flow in 2025. Those margins are what absorb tariff costs before they reach the payout. The Trump administration has also promoted a set of most-favored-nation drug-pricing agreements tied to TrumpRx.gov. Public White House materials list Johnson & Johnson, Pfizer, Merck, Bristol Myers Squibb, and others as having reached such agreements.
The relief pathways exist but carry real costs. The proclamation and related federal notices describe company-specific agreements and an onshoring-application process that can provide preferential Section 232 tariff treatment for qualifying companies. Getting to the most favorable treatment means accepting government pricing oversight alongside capital-intensive domestic manufacturing commitments.
For Pfizer and Merck, the calculus is more complicated. The main downside risk for both names is pharma tariffs or most-favored-nation drug pricing landing harder than expected. That risk is real, and neither yield is truly bulletproof. Keytruda is Merck’s largest product, but it does not drive roughly half of Merck’s pharmaceutical revenue. In Merck’s full-year 2025 results, Keytruda sales were about $31.6 billion versus Pharmaceutical segment revenue of about $58.1 billion, or roughly 54%. Layer a 100% tariff on imported APIs on top of that cliff, and the margin buffer shrinks from two directions at once.
The September 29 deadline does not automatically break any of these dividends. J&J’s free cash flow is substantial enough to absorb hundreds of millions in tariff costs and still fund the payout. But the question income investors should bring to this week’s conference webcasts is a narrow one: how much of the tariff cost has been quantified, how much has been passed through to pricing agreements, and how much still sits unresolved on the balance sheet? Managements that answer clearly are worth holding. Those that stay vague about costs sixteen days from a universal deadline deserve a closer look at the supply chain behind every dollar of yield they are promising.
